Capecitabine and Microangiopathic haemolytic anaemia - a phase IV clinical study of FDA data

Summary:

Microangiopathic haemolytic anaemia is reported as a side effect among people who take Capecitabine (capecitabine), especially for people who are male, 60+ old, have been taking the drug for 1 - 2 years also take Cisplatin, and have Gastric cancer.

The phase IV clinical study analyzes which people have Microangiopathic haemolytic anaemia when taking Capecitabine. It is created by eHealthMe based on reports of 59,451 people who have side effects when taking Capecitabine from the FDA, and is updated regularly.

What is Capecitabine?

Capecitabine has active ingredients of capecitabine. eHealthMe is studying from 59,495 Capecitabine users. Check the latest studies of Capecitabine.

What is Microangiopathic haemolytic anaemia?

Microangiopathic haemolytic anaemia (anaemia due to inability of bone marrow to compensate the premature destruction of red blood cells) is found to be associated with 94 drugs and 235 conditions by eHealthMe. Check the latest studies of Microangiopathic haemolytic anaemia.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 27, 2026

59,451 people reported to have side effects when taking Capecitabine.
Among them, 12 people (0.02%) have Microangiopathic haemolytic anaemia.

Could Capecitabine cause Microangiopathic haemolytic anaemia?

Among these 12 people:

How long have people been on Capecitabine when they have Microangiopathic haemolytic anaemia? *

What is the gender of people who have Microangiopathic haemolytic anaemia when taking Capecitabine? *

female: 20 %
male: 80 %

What is the age of people who have Microangiopathic haemolytic anaemia when taking Capecitabine? *

What are other drugs people take besides Capecitabine? *

What are other side effects people have besides Microangiopathic haemolytic anaemia? *

Thrombocytopenia (decrease of platelets in blood): 5 people, 41.67%
Thrombotic Microangiopathy (a pathology that results in thrombosis in capillaries and arterioles, due to an endothelial injury): 4 people, 33.33%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 3 people, 25.00%
High Blood Pressure: 3 people, 25.00%
Idiopathic Thrombocytopenic Purpura (Itp) (bleeding disorder in which the immune system destroys platelets, which are necessary for normal blood clotting): 2 people, 16.67%
Metastases To Liver (cancer spreads to liver): 2 people, 16.67%
Chills (felling of cold): 2 people, 16.67%
Blood Bilirubin Increased: 2 people, 16.67%
Back Pain: 2 people, 16.67%
Intravascular Haemolysis (intravascular rupture of red blood cells with the release of haemoglobin and the cellular constituents into the plasma, or liquid portion of whole blood): 2 people, 16.67%

What are the existing conditions these people have? *

Gastric Cancer (stomach cancer): 4 people, 33.33%
Rectal Cancer Stage Iv (rectal cancer has been carried through the lymph system to distant parts of the body): 3 people, 25.00%
Oesophageal Adenocarcinoma (a cancer tumour of an epithelium in oesophagus): 2 people, 16.67%
Metastases To Liver (cancer spreads to liver): 2 people, 16.67%
Rectal Cancer Metastatic (cancer of rectum spreads to other): 1 person, 8.33%
Metastasis (spreadable cancer to other organ from origin): 1 person, 8.33%
Breast Cancer Metastatic: 1 person, 8.33%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 1 person, 8.33%
Adenocarcinoma (malignant tumour formed from glandular structures in epithelial tissue): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Capecitabine and have Microangiopathic haemolytic anaemia?

- Check whether Microangiopathic haemolytic anaemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Capecitabine:

Capecitabine (59,495 reports)

Browse all side effects of Capecitabine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Microangiopathic haemolytic anaemia:

Microangiopathic haemolytic anaemia (94 drugs)

Browse all the conditions that are associated with Microangiopathic haemolytic anaemia:

Microangiopathic haemolytic anaemia (235 conditions)

Related publications that referenced our studies

Pinto HP, Bhat RM, Shet D, Dandekeri S, "Compound mucocutaneous adverse effects of oral capecitabine in a patient", Indian dermatology online journal, 2014 Jan .
Kang SM, Baek JY, Hwangbo B, Kim HY, Lee GK, Lee HS, "A case of capecitabine-induced sarcoidosis", Tuberculosis and respiratory diseases, 2012 Mar .
Pinto HP, Bhat RM, Shet D, Dandekeri S, "Compound mucocutaneous adverse effects of oral capecitabine in a patient", Indian dermatology online journal, 2014 Jan .
Kang SM, Baek JY, Hwangbo B, Kim HY, Lee GK, Lee HS, "A case of capecitabine-induced sarcoidosis", Tuberculosis and respiratory diseases, 2012 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on capecitabine (the active ingredients of Capecitabine) and Capecitabine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.